151 related articles for article (PubMed ID: 37823398)
1. RANK-L inhibitor as a promising agent for refractory extensive craniofacial fibrous dysplasia: A case report.
Abouammo MD; Alsavaf MB; Prevedello DM; Ghalib L; Boyce AM; Carrau RL
Head Neck; 2024 Jan; 46(1):E1-E5. PubMed ID: 37823398
[TBL] [Abstract][Full Text] [Related]
2. Craniofacial fibrous dysplasia associated with McCune-Albright syndrome: challenges in diagnosis and treatment: case reports.
Kabali TM; Moshy JR; Owibingire SS; Sohal KS; Simon ENM
BMC Oral Health; 2019 Aug; 19(1):180. PubMed ID: 31395055
[TBL] [Abstract][Full Text] [Related]
3. McCune-Albright syndrome with craniofacial dysplasia: Clinical review and surgical management.
Belsuzarri TA; Araujo JF; Melro CA; Neves MW; Navarro JN; Brito LG; Pontelli LO; de Abreu Mattos LG; Gonçales TF; Zeviani WM
Surg Neurol Int; 2016; 7(Suppl 6):S165-9. PubMed ID: 27057395
[TBL] [Abstract][Full Text] [Related]
4. Craniofacial Fibrous Dysplasia Involvements of Mccune-Albright Syndrome: A Review with an Additional Case.
Özcan İ; Ünsal G; Koca RB; Orhan K
Curr Med Imaging; 2021; 17(7):864-870. PubMed ID: 33297918
[TBL] [Abstract][Full Text] [Related]
5. A case of atypical McCune-Albright syndrome requiring optic nerve decompression.
Yavuzer R; Khilnani R; Jackson IT; Audet B
Ann Plast Surg; 1999 Oct; 43(4):430-5. PubMed ID: 10517473
[TBL] [Abstract][Full Text] [Related]
6. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
7. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.
Akintoye SO; Boyce AM; Collins MT
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Sep; 116(3):e149-55. PubMed ID: 23953425
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
[TBL] [Abstract][Full Text] [Related]
9. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.
Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E
Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748
[TBL] [Abstract][Full Text] [Related]
10. Optic neuropathy in McCune-Albright syndrome: an indication for aggressive treatment.
Bocca G; de Vries J; Cruysberg JR; Boers GH; Monnens LA
Acta Paediatr; 1998 May; 87(5):599-600. PubMed ID: 9641748
[TBL] [Abstract][Full Text] [Related]
11. Craniofacial Fibrous Dysplasia: Clinical and Therapeutic Implications.
Szymczuk V; Taylor J; Boyce AM
Curr Osteoporos Rep; 2023 Apr; 21(2):147-153. PubMed ID: 36849642
[TBL] [Abstract][Full Text] [Related]
12. Treatment of fibrous dysplasia: focus on denosumab.
Huzum B; Antoniu S; Dragomir R
Expert Opin Biol Ther; 2022 Mar; 22(3):397-405. PubMed ID: 34964677
[TBL] [Abstract][Full Text] [Related]
13. McCune Albright syndrome - association of fibrous dysplasia, café-au-lait skin spots and hyperthyroidism - case report.
Raus I; Coroiu RE
Clujul Med; 2016; 89(4):559-564. PubMed ID: 27857528
[TBL] [Abstract][Full Text] [Related]
14. A case of craniofacial fibrous dysplasia associated with McCune-Albright syndrome lost to follow-up.
Williams RG
BMJ Case Rep; 2015 Feb; 2015():. PubMed ID: 25721837
[TBL] [Abstract][Full Text] [Related]
15. Craniofacial fibrous dysplasia and aneurismal bone cyst in a patient with McCune-Albright syndrome. A case report and review of the literature.
Castro Castro J; Villa Fernández JM; Agulleiro Díaz JP
Neurocirugia (Astur : Engl Ed); 2023; 34(5):268-272. PubMed ID: 36192338
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
17. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
[TBL] [Abstract][Full Text] [Related]
18. [McCune-Albright syndrome revealed by Blaschko-linear café-au-lait spots on the back].
Jung AJ; Soskin S; Paris F; Lipsker D
Ann Dermatol Venereol; 2016 Jan; 143(1):21-6. PubMed ID: 26610360
[TBL] [Abstract][Full Text] [Related]
19. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
